OncLive TV

Aileen I. Fernandez, PhD, discusses the utility of fam-trastuzumab deruxtecan-nxki in HER2-low breast cancer.

Daniel C. Danila, MD, discusses ​the rationale for examining immunotherapy in early-stage prostate cancer.

Paolo Ghia, MD, PhD, discusses the design of the phase 2 CAPTIVATE study in treatment-naïve chronic lymphocytic leukemia.

Sara A. Hurvitz, MD, discusses the rationale for the phase 3 DESTINY-Breast03 trial examining in HER2-positive breast cancer.

Benjamin Heyman, MD, discusses the phase 3 SYMPATICO trial examining the combination of ibrutinib and venetoclax vs ibrutinib alone in patients with relapsed or refractory mantle cell lymphoma.

Tanya Dorff, MD, discusses the clinical implications of the phase 3 ARAMIS trial in nonmetastatic castration-resistant prostate cancer.

John F. Seymour, M​BBS, FRACP, PhD, discusses the design of the phase 3 ELEVATE-RR trial comparing acalabrutinib vs ibrutinib in chronic lymphocytic leukemia.

Shikha Jain, MD, FACP, discusses the importance of communication in patients with colorectal cancer and liver metastases who are receiving multidisciplinary care.

Peter Riedell, MD, discusses the effects of time to relapse on outcomes in mantle cell lymphoma.

Marina Kremyanskaya, MD, PhD, discusses the design of the phase 1/2 MANIFEST trial in myelofibrosis.

Hiromichi Shirasu, MD, discusses the clinical implications of the GALAXY trial as part of the CIRCULATE-Japan project, which is investigating circulating tumor DNA status in patients with resectable colorectal cancer.

Leonard G. Gomella, MD, discusses ongoing studies evaluating novel biomarkers in prostate cancer.

Amado J. Zurita-Saavedra, MD, discusses the utilization of the antiandrogen agents apalutamide and enzalutamide in patients with metastatic hormone-sensitive prostate cancer.

Kristen K. Ciombor, MD, MSCI, discusses the use of panitumumab in the maintenance treatment of patients with RAS wild-type metastatic colorectal cancer.

Joleen M. Hubbard, MD, discusses the design of the ongoing phase 2/3 NRG-GI005 trial in patients with stage IIA colorectal cancer after surgery.

Anil K. Sood, MD, discusses navigating frontline maintenance therapy in ovarian cancer.

Richard T. Penson, MD, MRCP, discusses selecting between PARP inhibitors for switch maintenance therapy in recurrent ovarian cancer.

Saum Ghodoussipour, MD, discusses ongoing trials in renal cell carcinoma and prostate cancer.

Tarek H. Mouhieddine, discusses a study that evaluated outcomes in patients with relapsed/refractory multiple myeloma who progressed on bispecific antibodies.

Naval Daver, MD, discusses the next steps for menin inhibitors in acute myeloid leukemia.

Gretchen G. Kimmick, MD, MS, discusses selecting adjuvant therapy for patients with HER2-positive breast cancer.

Christine Bestvina, MD, discusses the emerging role of neoadjuvant chemoimmunotherapy in lung cancer.

Tomer Mark, MD, discusses establishing minimal residual disease (MRD) as a surrogate marker for survival in multiple myeloma.

Charu Aggarwal, MD, MPH, discusses the significance of the phase 3 IMpower010 trial in patients with PD-L1–positive non–small cell lung cancer.

Jeffrey S. Weber, MD, PhD, discusses unmet needs in ocular and mucosal melanoma.

Cristina Gasparetto, MD, discusses how to manage keratopathy associated with treatment with belantamab mafodotin-blmf in patients with multiple myeloma.

Alexander J. Lazar, MD, PhD, discusses the current state of diagnosis and treatment in desmoid tumors.

Bilal A. Siddiqui, MD, discusses selecting between available antiandrogen agents in nonmetastatic castration-resistant prostate cancer.

Shikha Jain, MD, FACP, discusses the need to enroll heterogenous patient populations to clinical trials in colorectal cancer.

Matthew S. McKinney, MD, discusses the emergence of CAR T-cell therapy in relapsed/refractory mantle cell lymphoma.